143 related articles for article (PubMed ID: 34479374)
21. 18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas.
Kumar R; Xiu Y; Potenta S; Mavi A; Zhuang H; Yu JQ; Dhurairaj T; Dadparvar S; Alavi A
J Nucl Med; 2004 Nov; 45(11):1796-803. PubMed ID: 15534046
[TBL] [Abstract][Full Text] [Related]
22. Gastrointestinal Stromal Tumor of the Prostate: Staging and Evaluation of Response to Therapy With 18F-FDG PET/CT.
Alabed YZ
Clin Nucl Med; 2018 Jan; 43(1):52-54. PubMed ID: 29166334
[TBL] [Abstract][Full Text] [Related]
23. 18F-Fluorodeoxyglucose positron emission tomography in evaluating treatment response to imatinib or other drugs in gastrointestinal stromal tumors: a systematic review.
Treglia G; Mirk P; Stefanelli A; Rufini V; Giordano A; Bonomo L
Clin Imaging; 2012; 36(3):167-75. PubMed ID: 22542374
[TBL] [Abstract][Full Text] [Related]
24. Value of FDG-PET for monitoring treatment response in patients with advanced GIST refractory to high-dose imatinib. A multicenter GEIS study.
Fuster D; Ayuso JR; Poveda A; Cubedo R; Casado A; Martínez-Trufero J; López-Pousa A; Del Muro XG; Lomeña F; Maurel J; Pons F
Q J Nucl Med Mol Imaging; 2011 Dec; 55(6):680-7. PubMed ID: 21150863
[TBL] [Abstract][Full Text] [Related]
25. Postoperative FDG-PET/CT staging in GIST: is there a benefit following R0 resection?
Hahn S; Bauer S; Heusner TA; Ebeling P; Hamami ME; Stahl A; Forsting M; Bockisch A; Antoch G
Eur J Radiol; 2011 Dec; 80(3):670-4. PubMed ID: 20970938
[TBL] [Abstract][Full Text] [Related]
26. Response evaluation with
Taralli S; Lorusso M; Scolozzi V; Masiello V; Marazzi F; Calcagni ML
Ann Nucl Med; 2019 Mar; 33(3):193-200. PubMed ID: 30569442
[TBL] [Abstract][Full Text] [Related]
27. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).
Fledelius J; Khalil AA; Hjorthaug K; Frøkiaer J
J Med Imaging Radiat Oncol; 2016 Apr; 60(2):231-8. PubMed ID: 26678718
[TBL] [Abstract][Full Text] [Related]
28. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression.
Van den Abbeele AD; Gatsonis C; de Vries DJ; Melenevsky Y; Szot-Barnes A; Yap JT; Godwin AK; Rink L; Huang M; Blevins M; Sicks J; Eisenberg B; Siegel BA
J Nucl Med; 2012 Apr; 53(4):567-74. PubMed ID: 22381410
[TBL] [Abstract][Full Text] [Related]
29. Clinical significance of
Du W; Cui G; Wang K; Li S
Eur J Med Res; 2022 Sep; 27(1):182. PubMed ID: 36114563
[TBL] [Abstract][Full Text] [Related]
30. 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG.
Dimitrakopoulou-Strauss A; Hohenberger P; Haberkorn U; Mäcke HR; Eisenhut M; Strauss LG
J Nucl Med; 2007 Aug; 48(8):1245-50. PubMed ID: 17631559
[TBL] [Abstract][Full Text] [Related]
31. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
Choi H; Charnsangavej C; Faria SC; Macapinlac HA; Burgess MA; Patel SR; Chen LL; Podoloff DA; Benjamin RS
J Clin Oncol; 2007 May; 25(13):1753-9. PubMed ID: 17470865
[TBL] [Abstract][Full Text] [Related]
32. Clinical Indications and Impact on Management: Fourth and Subsequent Posttherapy Follow-up
Taghipour M; Marcus C; Sheikhbahaei S; Mena E; Prasad S; Jha AK; Solnes L; Subramaniam RM
J Nucl Med; 2017 May; 58(5):737-743. PubMed ID: 27811123
[TBL] [Abstract][Full Text] [Related]
33. F-18 FDG PET, CT, and MRI for detecting the malignant potential in patients with gastrointestinal stromal tumors: A protocol for a network meta-analysis of diagnostic test accuracy.
Wei K; Pan B; Yang H; Lu C; Ge L; Cao N
Medicine (Baltimore); 2018 Apr; 97(16):e0389. PubMed ID: 29668594
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic role of 18F-fluorodeoxyglucose positron emission tomography for follicular lymphoma with gastrointestinal involvement.
Iwamuro M; Okada H; Takata K; Shinagawa K; Fujiki S; Shiode J; Imagawa A; Araki M; Morito T; Nishimura M; Mizuno M; Inaba T; Suzuki S; Kawai Y; Yoshino T; Kawahara Y; Takaki A; Yamamoto K
World J Gastroenterol; 2012 Nov; 18(44):6427-36; discussion p.6434. PubMed ID: 23197888
[TBL] [Abstract][Full Text] [Related]
35. [The value of (18)F-FDG PET-CT imaging in predicting the malignant potential of GIST].
Li SX; Tang MD; Lin DY; Liu DJ; Lyu QH; Zhang JP; Cai ZH
Zhonghua Zhong Liu Za Zhi; 2017 Nov; 39(11):821-827. PubMed ID: 29151288
[No Abstract] [Full Text] [Related]
36. Assessment of early response to imatinib 800 mg after 400 mg progression by ¹⁸F-fluorodeoxyglucose PET in patients with metastatic gastrointestinal stromal tumors.
Chacón M; Eleta M; Espindola AR; Roca E; Méndez G; Rojo S; Pupareli C
Future Oncol; 2015; 11(6):953-64. PubMed ID: 25760976
[TBL] [Abstract][Full Text] [Related]
37. [F-18]fluorodeoxyglucose positron emission tomography and positron emission tomography: computed tomography in recurrent and metastatic cholangiocarcinoma.
Jadvar H; Henderson RW; Conti PS
J Comput Assist Tomogr; 2007; 31(2):223-8. PubMed ID: 17414758
[TBL] [Abstract][Full Text] [Related]
38. 3'-Deoxy-3'-
Kim JE; Chae SY; Kim JH; Kim HJ; Kim TW; Kim KP; Kim SY; Lee JL; Oh SJ; Kim JS; Ryu JS; Moon DH; Hong YS
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1713-1722. PubMed ID: 31041456
[TBL] [Abstract][Full Text] [Related]
39. Consensus report on the radiological management of patients with gastrointestinal stromal tumours (GIST): recommendations of the German GIST Imaging Working Group.
Kalkmann J; Zeile M; Antoch G; Berger F; Diederich S; Dinter D; Fink C; Janka R; Stattaus J;
Cancer Imaging; 2012 May; 12(1):126-35. PubMed ID: 22572545
[TBL] [Abstract][Full Text] [Related]
40. Sequential
Bomanji J; Sharma R; Mittal BR; Gambhir S; Qureshy A; Begum SMF; Paez D; Sathekge M; Vorster M; Sobic Saranovic D; Pusuwan P; Mann V; Vinjamuri S; Zumla A; Pascual TNB
Eur J Nucl Med Mol Imaging; 2020 Dec; 47(13):3118-3129. PubMed ID: 32483653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
